Home » Array BioPharma Advances ARRY-797 to Phase II
Array BioPharma Advances ARRY-797 to Phase II
Array BioPharma has started dosing ARRY-797, a small molecule p38 inhibitor, in a Phase II trial to evaluate the drug for treating pain in dental patients undergoing third molar extraction.
The randomized, double-blind, placebo-controlled, parallel-group trial will assess the safety, tolerability and analgesic efficacy of ARRY-797 dosed either after the operation or both before and after surgery.
The trial will enroll 150 patients and be conducted at two centers in the U.S., Array said.
Upcoming Events
-
07May
-
14May
-
30May